Global Cell and Gene Therapy Clinical Trials Market Size, Share and Trend Analysis Report 2021 –


DUBLIN – (COMMERCIAL THREAD) – The report “Global Cell and Gene Therapy Clinical Trials Market 2021-2028” has been added to offer.

The global cell and gene therapy clinical trials market size is expected to reach USD 45.4 billion by 2028, with a CAGR of 22.3%.

Increased funding, investments in research and development, and successful product launches are driving market growth.

Cell and Gene Therapies (CGT) represent the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although some of the earliest therapies received market approval in the United States, there are many promising therapies in development around the world.

The cell and gene therapy market has seen significant growth in recent years with pharmaceutical companies teaming up to create effective and accessible therapies for patients. As reported by PhRMA in 2019, there were 362 cell and gene therapies in clinical development in the United States, which is a 20% increase from 2018.

In addition, at the end of 2019, there were more than 1,000 clinical trials of cell and gene therapy underway, including 452 genetically modified and cell-based immuno-oncology, 352 gene therapies, 216 cell therapies and 46 tissue engineering.

In addition, investments are pouring into companies of various types, ranging from startups to major acquisitions by major biopharmaceutical companies. In 2019, 19 mergers and acquisitions worth over $ 156 billion were completed.

The most significant of these has been the acquisition of Celgene and its portfolio of multiple cell therapy assets by Bristol-Myers Squibb for $ 74 billion is expected to increase its stake in oncology treatments. Therefore, which is a notable increase since 2015, when merger and acquisition activity in the latter amounted to around $ 4 billion.

Highlights of the Cell and Gene Therapy Clinical Trials Market Report

  • By phase, the phase II segment held the largest share of over 50.0% in 2020 due to the large number of therapies currently in development in phase II

  • Based on indications, the oncology segment held the largest share of 47.0% in 2020 as oncology alone contributed to 600 CGT clinical trials out of around 1,000

  • North America dominated the global market with a share of 48.3% in 2020. This is largely attributed to a large number of clinical trial activity in the United States and favorable government support.

  • Asia-Pacific region is expected to grow at the fastest CAGR of 23.1% during the forecast period owing to the growing number of biotech companies focusing on CGTs

Cell and Gene Clinical Trials Market: Variables, Trends, and Scope

Mapping of penetration and growth prospects

Impact of the COVID-19 pandemic on clinical trial activity

  • Barriers to clinical trials:

  • Interrupted clinical trials:

  • Companies with phase I trial interruption

  • Companies with discontinuation of the phase 2 trial

  • Companies with discontinuation of the phase 3 trial

Market Driver Analysis

  • Growing interest in CGT

  • Favorable regulatory environment

  • Increase R&D funding

Analysis of market restrictions

Industry challenge

  • Creation of a highly tactile data center model

  • Collection of raw materials

  • Marketing issues


  • Drug approval and a strong cell and gene therapy pipeline

CGT trends


Impact of COVID-19 on the industry

  • Time-sensitive CGTs during the pandemic

Cell and Gene Therapy Clinical Trials Market Analysis Tools

  • Porter’s Five Forces Analysis

  • PESTEL analysis

Analysis of major transactions and strategic alliances

Companies mentioned

  • ICNE plc

  • IQVIA Holdings Inc.

  • International company PAREXEL

  • Covance inc.

  • Syneos Health

  • Charles River International Laboratories, Inc.

  • Medpace Holdings, Inc.

  • Novartis

  • Novotech

  • Veristat, LLC

For more information on this report, visit


Leave A Reply